Skip to main content

Advertisement

SpringerLink
Log in

Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

To summarize the available data on the prevalence, clinical repercussion, and diagnosis of primary aldosteronism (PA) and to discuss the SPAIN-ALDO registry’s findings, which is the largest PA patient registry in Spain.

Methods

A comprehensive review of the literature focused on the prevalence, clinical presentation and diagnosis of PA was performed.

Results

PA is the most common cause of secondary arterial hypertension. In addition, PA patients have a higher cardio-metabolic risk than patients with essential arterial hypertension matched by age, sex, and blood pressure levels. However, despite its high prevalence and associated metabolic and cardiovascular complications, PA remains largely under-recognized, with less than 2% of people in at-risk populations ever tested. The diagnostic investigation is a multistep process, including screening, confirmatory testing, and subtype differentiation of unilateral from bilateral PA forms. Data from the SPAIN-ALDO registry have shed light on the cardiometabolic impact of PA and about the limitations in the PA diagnosis of these patients in Spain.

Conclusions

The most common cause of secondary hypertension is PA. One of the most challenging aspects of the diagnosis is the differentiation between unilateral and bilateral PA because adrenal venous sampling is a difficult procedure that should be performed in experienced centers. Data from the SPAIN-ALDO registry have provided important information on the nationwide management of this pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. M. Reincke, I. Bancos, P. Mulatero, U.I. Scholl, M. Stowasser, T.A. Williams, Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 9, 876–892 (2021). https://doi.org/10.1016/S2213-8587(21)00210-2

    Article  PubMed  Google Scholar 

  2. P. Mulatero, S. Monticone, J. Deinum, L. Amar, A. Prejbisz, M.C. Zennaro et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38, 1919–1928 (2020). https://doi.org/10.1097/HJH.0000000000002510

    Article  CAS  PubMed  Google Scholar 

  3. G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006). https://doi.org/10.1016/j.jacc.2006.07.059

    Article  CAS  PubMed  Google Scholar 

  4. A.F. Turcu, J. Yang, A. Vaidya, Primary aldosteronism - a multidimensional syndrome. Nat. Rev. Endocrinol. 18, 665–682 (2022). https://doi.org/10.1038/S41574-022-00730-2

    Article  PubMed  Google Scholar 

  5. J. Burrello, S. Monticone, I. Losano, G. Cavaglià, F. Buffolo, M. Tetti et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 75, 1025–1033 (2020). https://doi.org/10.1161/HYPERTENSIONAHA.119.14063

    Article  CAS  PubMed  Google Scholar 

  6. S. Monticone, F. D’Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41–50 (2018). https://doi.org/10.1016/S2213-8587(17)30319-4

    Article  CAS  PubMed  Google Scholar 

  7. P. Mulatero, S. Monticone, C. Bertello, A. Viola, D. Tizzani, A. Iannaccone et al. Long-Term cardio- and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 98, 4826–4833 (2013). https://doi.org/10.1210/jc.2013-2805

    Article  CAS  PubMed  Google Scholar 

  8. S. Savard, L. Amar, P.F. Plouin, O. Steichen, Cardiovascular complications associated with primary aldosteronism: A controlled cross-sectional study. Hypertension 62, 331–336 (2013). https://doi.org/10.1161/HYPERTENSIONAHA.113.01060

    Article  CAS  PubMed  Google Scholar 

  9. J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916 (2016). https://doi.org/10.1210/jc.2015-4061

    Article  CAS  PubMed  Google Scholar 

  10. M. Araujo-Castro, P. Parra-Ramírez, Diagnosis of primary hyperaldosteronism. Med. Clin. (Barc) (2021) https://doi.org/10.1016/j.medcli.2021.10.012

  11. M. Araujo-Castro, Treatment of primary hyperaldosteronism. Med. Clin. (Barc.) 155, 302–308 (2020). https://doi.org/10.1016/j.medcli.2020.04.029

    Article  PubMed  Google Scholar 

  12. G. Berglund, O. Andersson, L. Wilhelmsen, Prevalence of primary and secondary hypertension: Studies in a random population sample. Br. Med. J. 2, 554–556 (1976). https://doi.org/10.1136/bmj.2.6035.554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. K. Hiramatsu, T. Yamada, Y. Yukimura, I. Komiya, K. Ichikawa, M. Ishihara et al. A Screening Test to Identify Aldosterone-Producing Adenoma by Measuring Plasma Renin Activity: Results in Hypertensive Patients. Arch. Intern. Med. 141, 1589–1593 (1981). https://doi.org/10.1001/archinte.1981.00340130033011

    Article  CAS  PubMed  Google Scholar 

  14. S.C. Käyser, T. Dekkers, H.J. Groenewoud, G.J. Van Der Wilt, J. Carel Bakx, M.C. Van Der Wel, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J. Clin. Endocrinol. Metab. 101 (2016) https://doi.org/10.1210/jc.2016-1472

  15. S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J. Am. Coll. Cardiol. 69, 1811–1820 (2017). https://doi.org/10.1016/j.jacc.2017.01.052

    Article  PubMed  Google Scholar 

  16. M. Araujo-Castro, M. Iturregui Guevara, M. Calatayud Gutiérrez, P. Parra Ramírez, P. Gracia Gimeno, F.A. Hanzu et al. Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol. Diabetes y. Nutr. 67, 408–419 (2020). https://doi.org/10.1016/j.endinu.2020.03.002

    Article  Google Scholar 

  17. J.W. Funder, R.M. Carey, C. Fardella, C.E. Gomez-Sanchez, F. Mantero, M. Stowasser et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266–3281 (2008). https://doi.org/10.1210/jc.2008-0104

    Article  CAS  PubMed  Google Scholar 

  18. P. Parra Ramírez, P. Martín Rojas-Marcos, M. Cuesta Hernández, J.G. Ruiz-Sánchez, C. Lamas Oliveira, F.A. Hanzu et al. First survey on the diagnosis and treatment of primary aldosteronism by Spanish Endocrinology and Nutrition specialists. Endocrinol. Diabetes y. Nutr. 70, 374–380 (2023). https://doi.org/10.1016/J.ENDIEN.2022.01.013

    Article  Google Scholar 

  19. A. Di Murro, L. Petramala, D. Cotesta, L. Zinnamosca, E. Crescenzi, C. Marinelli et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism. J. Renin-Angiotensin-Aldosterone Syst. 11, 165–172 (2010). https://doi.org/10.1177/1470320310366581

    Article  PubMed  Google Scholar 

  20. F. Buffolo, Q. Li, S. Monticone, D.A. Heinrich, A. Mattei, J. Pieroni et al. Primary aldosteronism and obstructive sleep apnea a cross-sectional multi-ethnic study. Hypertension 74, 1532–1540 (2019). https://doi.org/10.1161/HYPERTENSIONAHA.119.13833

    Article  CAS  PubMed  Google Scholar 

  21. T.M. Seccia, C. Letizia, M.L. Muiesan, S. Lerco, M. Cesari, V. Bisogni et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J. Hypertens. 38, 332–339 (2020). https://doi.org/10.1097/HJH.0000000000002250

    Article  CAS  PubMed  Google Scholar 

  22. A. Markou, T. Pappa, G. Kaltsas, A. Gouli, K. Mitsakis, P. Tsounas et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J. Clin. Endocrinol. Metab. 98, 1409–1416 (2013). https://doi.org/10.1210/jc.2012-3353

    Article  CAS  PubMed  Google Scholar 

  23. R. Baudrand, F.J. Guarda, C. Fardella, G. Hundemer, J. Brown, G. Williams et al. Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension 69, 950–956 (2017). https://doi.org/10.1161/HYPERTENSIONAHA.116.08952

    Article  CAS  PubMed  Google Scholar 

  24. J.M. Brown, M. Siddiqui, D.A. Calhoun, R.M. Carey, P.N. Hopkins, G.H. Williams et al. The unrecognized prevalence of primary aldosteronism a cross-sectional study. Ann. Intern. Med. 173, 10–20 (2020). https://doi.org/10.7326/M20-0065

    Article  PubMed  PubMed Central  Google Scholar 

  25. J.W. Funder, M. Reincke, Aldosterone: A cardiovascular risk factor? Biochim. Biophys. Acta - Mol. Basis Dis. 1802, 1188–1192 (2010). https://doi.org/10.1016/j.bbadis.2010.08.005

    Article  CAS  Google Scholar 

  26. C. Catena, G. Colussi, R. Lapenna, E. Nadalini, A. Chiuch, P. Gianfagna et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911–918 (2007). https://doi.org/10.1161/HYPERTENSIONAHA.107.095448

    Article  CAS  PubMed  Google Scholar 

  27. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005). https://doi.org/10.1016/j.jacc.2005.01.015

    Article  CAS  PubMed  Google Scholar 

  28. M. Reincke, E. Fischer, S. Gerum, K. Merkle, S. Schulz, A. Pallauf et al. Observational study mortality in treated primary aldosteronism: The German conn’s registry. Hypertension 60, 618–624 (2012). https://doi.org/10.1161/HYPERTENSIONAHA.112.197111

    Article  CAS  PubMed  Google Scholar 

  29. M. Fernández-Argüeso, E. Pascual-Corrales, N. Bengoa Rojano, A. García Cano, L. Jiménez Mendiguchía, M. Araujo-Castro, Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine 73, 439–446 (2021). https://doi.org/10.1007/s12020-021-02704-2

    Article  CAS  PubMed  Google Scholar 

  30. M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. González Boillos, E. Pascual-Corrales, A. García-Cano, et al. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications regarding cardiometabolic profile and surgical outcomes. Endocr. Connect. (2023) https://doi.org/10.1530/EC-23-0043

  31. H.H. Loh, N. Sukor, Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea—what do we know so far? J. Hum. Hypertens. 34 (2020) https://doi.org/10.1038/s41371-019-0294-8

  32. S. Shi, C. Lu, H. Tian, Y. Ren, T. Chen Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis. Front. Endocrinol. (Lausanne) 11 (2020) https://doi.org/10.3389/fendo.2020.574151

  33. M. Araujo-Castro, E. Pascual-Corrales, M. Fernández-Argüeso, N. Bengoa-Rojano, A. García Cano, L. Jiménez Mendiguchía, et al. The prevalence of primary and secondary hyperparathyroidism and its cardiometabolic implications in primary aldosteronism. Minerva Endocrinol. (2023) https://doi.org/10.23736/S2724-6507.23.03866-6

  34. A. Vaidya, R.M. Carey, Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J. Clin. Endocrinol. Metab. 105, 3771–3783 (2020). https://doi.org/10.1210/CLINEM/DGAA606

    Article  PubMed  PubMed Central  Google Scholar 

  35. R.M. Carey, D.A. Calhoun, G.L. Bakris, R.D. Brook, S.L. Daugherty, C.R. Dennison-Himmelfarb et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertens. (Dallas, Tex. 1979) 72, E53–E90 (2018). https://doi.org/10.1161/HYP.0000000000000084

    Article  CAS  Google Scholar 

  36. G.P. Rossi, V. Bisogni, A.V. Bacca, A. Belfiore, M. Cesari, A. Concistrè, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int. J. Cardiol. Hypertens. 5, (2020) https://doi.org/10.1016/j.ijchy.2020.100029

  37. G. Jaffe, Z. Gray, G. Krishnan, M. Stedman, Y. Zheng, J. Han et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertens. (Dallas, Tex. 1979) 75, 650–659 (2020). https://doi.org/10.1161/HYPERTENSIONAHA.119.14359

    Article  CAS  Google Scholar 

  38. M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. González Boillos, E. Pascual-Corrales, A.M. García Cano, et al. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry. J. Endocrinol. Investig. (2023) https://doi.org/10.1007/S40618-023-02090-8

  39. F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91, 454–459 (2006). https://doi.org/10.1210/jc.2005-1733

    Article  CAS  PubMed  Google Scholar 

  40. M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s registry. Horm. Metab. Res 42, 435–439 (2010). https://doi.org/10.1055/s-0029-1246189

    Article  CAS  PubMed  Google Scholar 

  41. J. Franch Nadal, M. Mata Cases, D. Mauricio Puente, Epidemiology and clinical management of type 2 diabetes mellitus and associated comorbidities in Spain (e-Management study). Med Clin. (Barc.) 147(Suppl 1), 1–7 (2016). https://doi.org/10.1016/S0025-7753(17)30618-8

    Article  PubMed  Google Scholar 

  42. G.P. Rossi, G. Ceolotto, G. Rossitto, T.M. Seccia, G. Maiolino, C. Berton et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin. Chem. Lab. Med. 54, 1441–1450 (2016). https://doi.org/10.1515/CCLM-2015-1094

    Article  CAS  PubMed  Google Scholar 

  43. L.K. Wolfe, R.D. Gordon, D.P. Island, G.W. Liddle, An analysis of factors determining the circadian pattern of aldosterone excretion. J. Clin. Endocrinol. Metab. 26, 1261–1266 (1966). https://doi.org/10.1210/JCEM-26-11-1261

    Article  CAS  PubMed  Google Scholar 

  44. M. Stowasser, A.H. Ahmed, E. Pimenta, P.J. Taylor, R.D. Gordon, Factors affecting the aldosterone/renin ratio. Horm. Metab. Res. 44 (2012) https://doi.org/10.1055/s-0031-1295460

  45. N. Yozamp, G.L. Hundemer, M. Moussa, J. Underhill, T. Fudim, B. Sacks et al. Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection. Hypertens. (Dallas, Tex. 1979) 77, 891–899 (2021). https://doi.org/10.1161/HYPERTENSIONAHA.120.16429

    Article  CAS  Google Scholar 

  46. A. Tanabe, M. Naruse, S. Takagi, K. Tsuchiya, T. Imaki, K. Takano, Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J. Clin. Endocrinol. Metab. 88, 2489–2494 (2003). https://doi.org/10.1210/jc.2002-021476

    Article  CAS  PubMed  Google Scholar 

  47. M. Araujo-Castro, M. Paja Fano, M. González Boillos, B. Pla Peris, E. Pascual-Corrales, A.M. García Cano et al. Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry. Endocrine 76, 687–696 (2022). https://doi.org/10.1007/S12020-022-03029-4

    Article  CAS  PubMed  Google Scholar 

  48. R. Libianto, M. Stowasser, G. Russell, P.J. Fuller, J. Yang, Improving Detection Rates for Primary Aldosteronism. Exp. Clin. Endocrinol. Diabetes (2023) https://doi.org/10.1055/A-2048-6213

  49. E. Ng, S.M. Gwini, W. Zheng, P.J. Fuller, J. Yang, Predicting bilateral subtypes of primary aldosteronism without adrenal vein sampling: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. (2023) https://doi.org/10.1210/CLINEM/DGAD451

  50. T. Nishikawa, M. Omura, F. Satoh, H. Shibata, K. Takahashi, N. Tamura et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr. J. 58, 711–721 (2011). https://doi.org/10.1507/ENDOCRJ.EJ11-0133

    Article  CAS  PubMed  Google Scholar 

  51. H. Hashimura, J. Shen, P.J. Fuller, N.Y.N. Chee, J.C.G. Doery, W. Chong et al. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism. Clin. Endocrinol. (Oxf.) 89, 308–313 (2018). https://doi.org/10.1111/CEN.13757

    Article  CAS  PubMed  Google Scholar 

  52. N. Wada, A. Miyoshi, H. Usubuchi, S. Terae, Y. Shibayama, B. Takahashi et al. Prediction of unilateral hyperaldosteronism on adrenal vein sampling using captopril challenge test in patients with primary aldosteronism. Endocr. J. 68, 45–51 (2021). https://doi.org/10.1507/ENDOCRJ.EJ20-0329

    Article  CAS  PubMed  Google Scholar 

  53. T. Kocjan, G. Vidmar, P. Popović, M. Stanković, Validation of three novel clinical prediction tools for primary aldosteronism subtyping. Endocr Connect 2022;11 https://doi.org/10.1530/EC-21-0532

  54. T.J. Burton, I.S. Mackenzie, K. Balan, B. Koo, N. Bird, D.V. Soloviev et al. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J. Clin. Endocrinol. Metab. 97, 100–109 (2012). https://doi.org/10.1210/jc.2011-1537

    Article  CAS  PubMed  Google Scholar 

  55. A. Saiga, H. Yokota, H. Nagano, K. Sawada, Y. Kubota, T. Wada et al. 131I-6β-iodomethyl-19-norcholesterol adrenal scintigraphy as an alternative to adrenal venous sampling in differentiating aldosterone-producing adenoma from bilateral idiopathic hyperaldosteronism. Nucl. Med. Commun. 41, 1226–1233 (2020). https://doi.org/10.1097/MNM.0000000000001293

    Article  CAS  PubMed  Google Scholar 

  56. M. Araujo-Castro, M. Paja Fano, M. González Boillos, E. Pascual-Corrales, A.M. García Cano, P. Parra Ramírez et al. Diagnostic Accuracy of Adrenal Iodine-131 6-Beta-Iodomethyl-19-Norcholesterol Scintigraphy for the Subtyping of Primary Aldosteronism. Biomedicines 11, 1934 (2023). https://doi.org/10.3390/BIOMEDICINES11071934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. P. Mulatero, L.A. Sechi, T.A. Williams, J.W.M. Lenders, M. Reincke, F. Satoh et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1929–1936 (2020). https://doi.org/10.1097/HJH.0000000000002520

    Article  CAS  PubMed  Google Scholar 

  58. M. Araujo-Castro, M. Paja Fano, M. González Boillos, B. Pla Peris, E. Pascual-Corrales, A.M. García Cano et al. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register). Endocrine 78, 363–372 (2022). https://doi.org/10.1007/S12020-022-03122-8

    Article  CAS  PubMed  Google Scholar 

  59. S. Monticone, A. Viola, D. Rossato, F. Veglio, M. Reincke, C. Gomez-Sanchez et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 3, 296–303 (2015). https://doi.org/10.1016/S2213-8587(14)70069-5

    Article  CAS  PubMed  Google Scholar 

  60. A.T. Nanba, T. Wannachalee, J.J. Shields, J.B. Byrd, W.E. Rainey, R.J. Auchus et al. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism. J. Clin. Endocrinol. Metab. 104, 487–492 (2018). https://doi.org/10.1210/jc.2018-01299

    Article  PubMed Central  Google Scholar 

  61. M. Haase, A. Riester, P. Kröpil, S. Hahner, C. Degenhart, H.S. Willenberg et al. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J. Clin. Endocrinol. Metab. 99, 4397–4402 (2014). https://doi.org/10.1210/jc.2014-2788

    Article  CAS  PubMed  Google Scholar 

  62. G.P. Rossi, G. Maiolino, T.M. Seccia, R. GP, M. G, S. TM Adrenal Venous Sampling: Where Do We Stand? Endocrinol. Metab. Clin. North Am. 48, (2019) https://doi.org/10.1016/j.ecl.2019.08.012.

  63. T. Unger, C. Borghi, F. Charchar, N.A. Khan, N.R. Poulter, D. Prabhakaran et al. 2020 International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 38, 982–1004 (2020). https://doi.org/10.1097/HJH.0000000000002453

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

    Marta Araujo-Castro & Eider Pascual-Corrales

  2. University of Alcalá, Madrid, Spain

    Marta Araujo-Castro

  3. Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain

    Marta Araujo-Castro & Eider Pascual-Corrales

  4. Endocrinology & Nutrition Department, Hospital Universitario La Paz Madrid, Madrid, Spain

    Patricia Martín Rojas & Paola Parra Ramírez

Authors
  1. Marta Araujo-Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eider Pascual-Corrales
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia Martín Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Parra Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marta Araujo-Castro or Paola Parra Ramírez.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Araujo-Castro, M., Pascual-Corrales, E., Martín Rojas, P. et al. Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?. Endocrine 83, 527–536 (2024). https://doi.org/10.1007/s12020-023-03573-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03573-7

Keywords

Search

Navigation